CRO Work Flow Shifts To More Early-Stage Studies, Covance CEO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry could see further growth as pharma and biotech companies reassess the drug development paradigm.
You may also be interested in...
Novartis Head Of Pharma Development James Shannon: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
The company is moving forward with a new drug development paradigm and its “category captainship” program.
Future BIO Global Efforts Include International Relations, Greenwood Says
HAMBURG, Germany - Due to the increasingly global nature of biotechnology, the Biotechnology Industry Organization's board of directors will meet next month to discuss a proposal to expand its global reach and potentially create a department of international relations, BIO President Jim Greenwood said Nov. 13
Hospira’s Mayne Event: Acquisition Strengthens Oncology Portfolio
Merger will create the leading generic injectable pharmaceutical company in the world.